Evidence map›Paper›PMID 40728545›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Genomic characterization of clonal B-cell lymphocytosis of marginal zone origin with MYC rearrangements.

Ramón Diez-Feijóo, Mar Teixidó, Ana Ferrer, Marta Lafuente, María Rodriguez-Rivera, Anna Puiggros, Xavier Calvo, Luis Colomo, Bárbara Tazón-Vega, Cristina López and 7 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ramón Diez-Feijóo *Department of Hematology, Hospital del Mar, Barcelona, Spain. rdiez-feijoo@hmar.cat.ORCID http://orcid.org/0000-0003-3137-3443
Mar Teixidó *Pathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Ana FerrerPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Marta LafuenteApplied Clinical Research in Hematological Malignancies, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
María Rodriguez-RiveraPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Anna PuiggrosPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Xavier CalvoPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Luis ColomoPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Bárbara Tazón-VegaApplied Clinical Research in Hematological Malignancies, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
Cristina LópezHematopathology Section, Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Guillem ClotDepartament de Fonaments Clínics, Universitat de Barcelona, Barcelona, Spain.
Blanca Sanchez-GonzalezDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Christelle FerráDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Beatriz BellosilloApplied Clinical Research in Hematological Malignancies, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
Blanca EspinetPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.
Antonio SalarApplied Clinical Research in Hematological Malignancies, Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
Marta SalidoPathology Department, Molecular Cytogenetics, Molecular Diagnostic and Hematological Cytology Laboratories, Hospital del Mar, Barcelona, Spain.

Funding

Departament de Salut, Generalitat de Catalunya 2021SGR00628Instituto de Salud Carlos III FIS-FEDER PI19/00034
6 · The paper itself

Abstract

Monoclonal B-cell lymphocytosis of marginal zone origin (MBL-MZ) is an indolent clonal disorder with potential progression to lymphoma. MYC rearrangements (MYCr), typically linked to aggressive B-cell lymphomas, have not been reported in MBL-MZ. We describe three MBL-MZ cases with MYCr and TP53 alterations, detected via karyotyping, FISH, and optical genome mapping. We genetically characterized these cases by NGS using a custom panel including 31 MZ-related genes, and we assessed MYC expression via RNA-Seq. Despite harboring these high-risk alterations, all cases exhibited stable clinical courses without lymphoma transformation. These findings suggest MYCr alone may not drive aggressive behavior in MBL-MZ, underscoring the need for integrated genetic and clinical assessment to prevent overtreatment.

Indexed as

Biomarkers, TumorB-LymphocytesGene RearrangementLymphocytosisLymphoma, B-Cell, Marginal ZoneProto-Oncogene Proteins c-mycAgedFemaleGenetic Predisposition to DiseaseHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedTumor Suppressor Protein p53Biomarkers, TumorMYC protein, humanProto-Oncogene Proteins c-mycTP53 protein, humanTumor Suppressor Protein p53Monoclonal B-cell lymphocytosisMYC rearrangementsSplenic marginal zone lymphoma

Identifiers

PMID40728545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.